Diagnosing Alzheimer’s disease is a multi-step process that typically involves cognitive testing, brain imaging, and increasingly, biomarker tests that detect the disease’s biological hallmarks in spinal fluid or blood. There is no single test that confirms Alzheimer’s on its own. Instead, doctors piece together results from several evaluations, sometimes over multiple appointments spanning weeks or months, to reach a diagnosis and rule out other causes of memory loss.
It Starts With Cognitive Testing
The first step is usually a set of structured tests that measure memory, attention, language, and problem-solving. Two of the most common are the Mini-Mental State Exam (MMSE) and the Montreal Cognitive Assessment (MoCA). Both take roughly 10 to 15 minutes and involve tasks like recalling a short list of words, drawing a clock face, or following multi-step instructions. A MoCA score around 18 or below raises concern for Alzheimer’s, though no universal cutoff has been established for either test. Scores vary depending on age, education level, and other factors, so doctors interpret them in context rather than relying on a single number.
Beyond these screening tools, a full evaluation includes a detailed medical and neurobehavioral history, often gathered from both the patient and a close family member. A doctor will ask about the timeline of symptoms, how they affect daily activities, and whether personality or behavior has changed. A physical exam and standard blood tests are part of this stage too, primarily to rule out reversible causes of cognitive decline like thyroid problems, vitamin deficiencies, or infections.
Brain Imaging: What Doctors Look For
Structural brain imaging, usually an MRI, plays a key role in the workup. Doctors look for shrinkage in the hippocampus, the brain’s memory center. In Alzheimer’s, this region loses volume progressively. Research has shown that nearly all hippocampal subregions shrink significantly as the disease advances, and some of these changes can be detected even before symptoms appear. People who later convert from normal cognition to early dementia already show measurable volume loss in specific parts of the hippocampus compared to those who remain cognitively stable.
An MRI also helps doctors spot other explanations for cognitive decline, such as strokes, tumors, or fluid buildup in the brain. This is one reason imaging is considered essential before moving to more specialized tests.
PET Scans for Amyloid and Tau
When there is still significant uncertainty after the initial workup, a doctor may order a PET scan. Two types are used in Alzheimer’s diagnosis. Amyloid PET scans detect the sticky protein plaques that accumulate between brain cells in Alzheimer’s. Tau PET scans detect tangled protein fibers that form inside neurons. Both provide direct visual evidence of the disease’s biological signature.
Updated guidelines from the Alzheimer’s Association and the Society for Nuclear Medicine specify that PET scans are appropriate when a dementia specialist has completed a comprehensive evaluation, Alzheimer’s is a diagnostic possibility, and knowing whether amyloid or tau is present would change the treatment plan. This is especially relevant now that amyloid-lowering therapies exist, since confirming amyloid plaques is a prerequisite for those treatments. PET scans are not meant to replace the clinical exam or serve as a standalone screening tool.
Biomarker Tests: Spinal Fluid and Blood
Alzheimer’s disease is increasingly defined by its biology rather than its symptoms alone. The 2024 diagnostic criteria from the National Institute on Aging and the Alzheimer’s Association characterize the disease as a biological continuum, from invisible brain changes years before symptoms appear through progressive cognitive decline. Diagnosis under this framework depends on identifying abnormal biomarkers.
Cerebrospinal fluid (CSF) testing, done through a lumbar puncture, measures levels of two key proteins. One is amyloid-beta 42, which drops in spinal fluid when it gets trapped in brain plaques instead of flowing freely. The other is phosphorylated tau (p-tau), which rises as tau tangles form. The ratio between these two proteins is particularly telling. Mayo Clinic Laboratories uses a p-tau to amyloid-beta 42 ratio cutoff of 0.028: a ratio at or below that level agrees with a normal amyloid PET scan 92% of the time, while a ratio above it agrees with an abnormal PET scan 92% of the time.
These biomarkers feed into a classification system that researchers and clinicians call the ATN framework, which stands for Amyloid, Tau, and Neurodegeneration. Each component is rated as normal or abnormal based on fluid tests or imaging. A person with abnormal amyloid alone falls on the “Alzheimer’s continuum.” When both amyloid and tau are abnormal, regardless of the neurodegeneration marker, that combination denotes Alzheimer’s disease.
Blood Tests: A Newer, Simpler Option
Blood-based biomarker tests represent a major shift in how Alzheimer’s can be detected. The most promising measures a form of tau protein called p-tau217 in the blood, which reflects both amyloid plaque buildup and tau pathology in the brain. An FDA-cleared blood test using this marker showed 99% sensitivity and 85% specificity in a research cohort, with 95% overall diagnostic accuracy. That means it catches nearly every true case and correctly identifies most people who don’t have the disease.
Real-world performance has been more mixed. When the same test was evaluated in a clinical population (patients referred from regular medical practice rather than carefully selected research participants), sensitivity held at 100% but specificity dropped to 23%, meaning many people without Alzheimer’s received a positive result. This gap highlights that blood tests are best used as part of the broader diagnostic workup, not as a definitive answer on their own. Still, they offer a much less invasive starting point than a spinal tap or PET scan, and they’re likely to play a growing role in primary care settings.
Genetic Testing and Risk Assessment
You may have heard about the APOE gene, particularly the APOE4 variant, which is the strongest known genetic risk factor for late-onset Alzheimer’s. Genetic testing can identify whether you carry one or two copies of this variant, but the results are not a diagnosis. Many people with APOE4 never develop Alzheimer’s, and many people without it do. The test identifies a risk factor, not the disease itself.
A doctor might recommend APOE testing if you’ve already been diagnosed with Alzheimer’s, since your genetic profile can help guide treatment decisions, particularly regarding newer targeted therapies where APOE4 status affects both eligibility and risk of side effects. For people without symptoms, the test is voluntary and comes with the complexity of learning about a risk you may or may not be able to act on.
How Long the Process Takes
The full diagnostic workup can stretch over several appointments and many months, though in some cases a diagnosis comes together more quickly. A typical path might begin with a visit to your primary care doctor, who performs initial cognitive screening and orders blood work and an MRI. If results point toward a neurodegenerative cause, you’re referred to a neurologist or memory clinic for more specialized testing, which could include CSF analysis, PET imaging, or blood-based biomarker tests.
Each of these steps involves scheduling, waiting for results, and sometimes repeating tests to confirm findings. The process can feel slow, but the layered approach exists because so many conditions mimic Alzheimer’s symptoms, including depression, medication side effects, other forms of dementia, and normal age-related memory changes. Getting the diagnosis right matters enormously, both for accessing appropriate treatment and for planning ahead.